CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc., a pharmaceutical company focused on developing new treatments for amyotrophic lateral sclerosis (ALS), Alzheimer’s disease and other neurodegenerative diseases, today announced the appointment of Chris Aiello to Head of Canada and General Manager. Mr. Aiello’s prior experience in overseeing multiple biotechnology companies’ Canadian operations and launches will be instrumental in Amylyx’ efforts to bring potential treatments to people living with neurodegenerative diseases in Canada.
“The addition of Chris to our team is part of our commitment to work as expeditiously as possible to bring AMX0035 through the regulatory approval process for the potential treatment of ALS,” said Joshua Cohen, Co-CEO, Chairman and Co-Founder of Amylyx.
“As we continue conversations with Health Canada and as the company enters this next phase of growth and expansion, Chris will be essential in helping us serve people living with ALS,” added Justin Klee, Co-CEO and Co-Founder of Amylyx.
Amylyx recently announced plans to submit a New Drug Submission (NDS) for AMX0035 for the treatment of ALS with Health Canada; Mr. Aiello will be responsible for leading Canadian operations and launch preparations.
"I am thrilled to be joining Amylyx at this time of exciting growth and opportunity in Canada," said Chris Aiello. "I have a passion to do what is right for patients. I am privileged to have this opportunity to support the Canadian ALS community who have been left without answers for too long.”
Mr. Aiello has experience across multiple therapeutic areas, including rare diseases. Mr. Aiello joins Amylyx most recently from Sanofi Genzyme Canada, where he served as the Business Unit Director of both the Rare Disease and the Rare Blood Disorders units. He led new therapy launches, built and strengthened external relationships within the Canadian communities the company served and managed sales and marketing to ensure business goals were achieved. Prior, Mr. Aiello was the General Manager of Canada for Bioverativ, which was ultimately purchased by Sanofi Genzyme.
“Chris is a strategic leader with a solid track-record of results and a passion for building and leading high-performance teams. His background in managing successful operations in Canada and his experience in rare disease therapeutics makes him a strong leader, who will greatly contribute to Amylyx’ commitment to bringing our investigational product, AMX0035, through the regulatory approval process as quickly as possible in Canada,” said Margaret Olinger, Chief Commercial Officer of Amylyx. “I am looking forward to working closely with Chris to accomplish our goals in Canada.”
About Amylyx Pharmaceuticals
Amylyx Pharmaceuticals, Inc. is a pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis (ALS), Alzheimer’s disease and other neurodegenerative diseases. For more information, visit www.amylyx.com and follow us on LinkedIn and Twitter.
